Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Jayendra Patel

Psychiatry Lake Charles, LA Medical Doctor

NPI 1467434191 CMS profile 247521

333 Dr Michael Debakey Dr, Ste. 220, Lake Charles, LA 70601

Open in the dashboard

General payments

$12,522

207 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Jayendra Patel of Lake Charles, LA is reported in the CMS Open Payments database as having received $12,522 across 207 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $16 1
2023 General $51 3
2022 General $335 20
2021 General $909 60
2020 General $4,806 59
2019 General $6,407 64

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jayendra Patel
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Jayendra Patel were reported at $0. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Jayendra Patel Psychiatry median Middle half National median
2019 $6,407 $184 $59–$605 $163
2020 $4,806 $119 $36–$372 $114
2021 $909 $143 $43–$576 $132
2022 $335 $153 $50–$590 $149
2023 $51 $170 $56–$651 $160
2024 $16 $179 $57–$673 $164
2025 $0 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Otsuka America Pharmaceutical, Inc. $9,982 47 payments
  2. Sunovion Pharmaceuticals Inc. $538 40 payments
  3. Neurocrine Biosciences, Inc. $416 19 payments
  4. Janssen Pharmaceuticals, Inc $389 25 payments
  5. AbbVie, Inc. $354 20 payments
  6. Allergan Inc. $165 15 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $163 10 payments
  8. Alkermes, Inc. $139 9 payments
  9. Vanda Pharmaceuticals Inc. $135 8 payments
  10. Lundbeck LLC $67 4 payments
  11. Other $174 10 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $8,374 7 payments
  2. Food and Beverage $3,273 197 payments
  3. Travel and Lodging $875 3 payments
Products named General payments · program years 2019–2024
  1. ABILIFY MAINTENA $9,897 42 payments
  2. REXULTI $1,182 14 payments
  3. LATUDA $538 40 payments
  4. INGREZZA $381 17 payments
  5. VRAYLAR Neuroscience $354 20 payments
  6. SPRAVATO $322 21 payments
  7. INVEGA SUSTENNA $250 16 payments
  8. INVEGA TRINZA $195 13 payments
  9. VRAYLAR Neuroscience $165 15 payments
  10. ARISTADA INITIO $139 9 payments
  11. Other $1,430 90 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

79

Median for Psychiatry: 574

Drug cost

$705

Median for Psychiatry: $27,624

Branded share of claims

0%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Clozapine Generic 12 $296
Risperidone Generic 27 $255
Quetiapine Fumarate Generic 11 $74
Trazodone Hcl Generic 15 $42
Escitalopram Oxalate Generic 14 $38

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 13 billing codes

Paid by Medicare

$4,464

Medicare's payments for the services billed

Medicare patients

19

Average age 46

Services billed

56

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Heart failure 0%
Atrial fibrillation 0%
Cancer 0%
Alzheimer's or dementia 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

207 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Louisiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record